Advances in nanomedicine for the treatment of Alzheimer's and Parkinson's diseases

被引:32
|
作者
Hernando, Sara [1 ,2 ]
Gartziandia, Oihane [1 ,2 ]
Herran, Enara [1 ,2 ]
Luis Pedraz, Jose [1 ,2 ]
Igartua, Manoli [1 ,2 ]
Maria Hernandez, Rosa [1 ,2 ]
机构
[1] Univ Basque Country, UPV EHU, Sch Pharm, Lab Pharmaceut,NanoBioCel Grp, Vitoria 01006, Spain
[2] Biomed Res Networking Ctr Bioengn Biomat & Nano, Vitoria 01006, Spain
关键词
Alzheimer's disease; drug delivery systems; nanomedicine; nanotechnology; Parkinson's disease; SOLID LIPID NANOPARTICLES; BLOOD-BRAIN-BARRIER; SUBCHRONIC INTRAMUSCULAR TOXICITY; LEVODOPA METHYL ESTER/BENSERAZIDE; ROTIGOTINE-LOADED MICROSPHERES; ADENOASSOCIATED VIRAL VECTORS; FIBROBLAST-GROWTH-FACTOR; CENTRAL-NERVOUS-SYSTEM; APP/PS1 MOUSE MODEL; NEUROTROPHIC FACTOR;
D O I
10.2217/nnm-2016-0019
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Alzheimer's disease and Parkinson's disease are the most common neurodegenerative diseases worldwide. Despite all the efforts made by the scientific community, current available treatments have limited effectiveness, without halting the progression of the disease. That is why, new molecules such as growth factors, antioxidants and metal chelators have been raised as new therapeutical approaches. However, these molecules have difficulties to cross the blood-brain barrier limiting its therapeutic effect. The development of nanometric drug delivery systems may permit a targeted and sustained release of old and new treatments offering a novel strategy to treat these neurodegenerative disorders. This review summarized the main investigated drug delivery systems as promising approaches to treat Alzheimer's disease and Parkinson's disease.
引用
收藏
页码:1267 / 1285
页数:19
相关论文
共 50 条
  • [41] Mismatch negativity in aging and in Alzheimer's and Parkinson's diseases
    Pekkonen, E
    AUDIOLOGY AND NEURO-OTOLOGY, 2000, 5 (3-4) : 216 - 224
  • [42] Proteomics in animal models of Alzheimer's and Parkinson's diseases
    Sowell, Rena A.
    Owen, Joshua B.
    Butterfield, D. Allan
    AGEING RESEARCH REVIEWS, 2009, 8 (01) : 1 - 17
  • [43] Arguments for Alzheimer's and Parkinson's diseases caused by prions
    Prusiner, Stanley B.
    PRION, 2019, 13 : 4 - 4
  • [44] Mitochondrial DNA in pathogenesis of Alzheimer's and Parkinson's diseases
    Maruszak, Aleksandra
    Gaweda-Walerych, Katarzyna
    Soltyszewski, Ireneusz
    Kekanowski, Cezary
    ACTA NEUROBIOLOGIAE EXPERIMENTALIS, 2006, 66 (02) : 153 - 176
  • [45] Vulnerability of cortical neurons to Alzheimer's and Parkinson's diseases
    Braak, Heiko
    Rueb, Udo
    Schultz, Christian
    Del Tredici, Kelly
    JOURNAL OF ALZHEIMERS DISEASE, 2006, 9 : 35 - 44
  • [46] Facial emotion expressivity in Parkinson's and Alzheimer's diseases
    Cannavacciuolo, A.
    Colella, D.
    Salzillo, M.
    De Biase, A.
    Paparella, G.
    Canevelli, M.
    Bruno, G.
    Berardelli, A.
    Berardelli, A.
    Bologna, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 437 - 437
  • [47] Parkinson's and Alzheimer's diseases - Protein aggregations and neuroprotection
    Gozes, I
    JOURNAL OF MOLECULAR NEUROSCIENCE, 2004, 24 (03) : 333 - 336
  • [48] Lymphocytes: model of study in Alzheimer's and Parkinson's diseases
    Jimenez Del Rio, Marlene
    Velez-Pardo, Carlos
    IATREIA, 2006, 19 (01) : 47 - 61
  • [49] Impaired Neurotransmitter Release in Alzheimer's and Parkinson's Diseases
    Shen, Jie
    NEURODEGENERATIVE DISEASES, 2010, 7 (1-3) : 80 - 83
  • [50] The aging immune system in Alzheimer's and Parkinson's diseases
    Heavener, Kelsey S.
    Bradshaw, Elizabeth M.
    SEMINARS IN IMMUNOPATHOLOGY, 2022, 44 (05) : 649 - 657